Literature DB >> 9243242

Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy.

C W Lam1, C H Lau, J C Williams, Y W Chan, L J Wong.   

Abstract

UNLABELLED: We report in this study a patient who developed repeated convulsions as a result of valproate therapy. MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) was subsequently diagnosed and a nucleotide 3243 A-->G mutation was detected in the mitochondrial DNA. This mutation predisposes the patient to the detrimental effects of valproate on oxidative phosphorylation.
CONCLUSION: We support the suggestion of Ponchaut et al. [14] that valproate should not be given to patients suspected of having mitochondrial diseases. In addition, for patients whose seizures worsen with valproate therapy, an inborn error of mitochondrial metabolism should be suspected. The underlying mitochondrial DNA defects should be sought for family screening and genetic counselling.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9243242     DOI: 10.1007/s004310050663

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  17 in total

1.  Melas syndrome.

Authors:  S K Singh; D Sarin; J M Puliyel; R Srivastav; R Gupta; N Kumar; A Mathews
Journal:  Indian J Pediatr       Date:  1999 Jul-Aug       Impact factor: 1.967

2.  Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mitochondrial DNA.

Authors:  Chih-Ming Lin; Peterus Thajeb
Journal:  Metab Brain Dis       Date:  2007-01-17       Impact factor: 3.584

Review 3.  The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options.

Authors:  Fernando Scaglia; Jennifer L Northrop
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Maternally inherited deafness and unusual phenotypic manifestations associated with A3243G mitochondrial DNA mutation.

Authors:  Katalin Komlósi; Richárd Kellermayer; Anita Maász; Viktória Havasi; Katalin Hollódy; Olga Vincze; Hajnalka Merkli; Endre Pál; Béla Melegh
Journal:  Pathol Oncol Res       Date:  2005-07-01       Impact factor: 3.201

Review 5.  Etiology and therapeutic approach to elevated lactate levels.

Authors:  Lars W Andersen; Julie Mackenhauer; Jonathan C Roberts; Katherine M Berg; Michael N Cocchi; Michael W Donnino
Journal:  Mayo Clin Proc       Date:  2013-10       Impact factor: 7.616

6.  A Case of Myopathy, Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS) Syndrome with Intracardiac Thrombus [corrected].

Authors:  Jung-Chul Joo; Myung Do Seol; Jin Won Yoon; Young Soo Lee; Dong-Keun Kim; Yong Hoon Choi; Hyo Seong Ahn; Wook Hyun Cho
Journal:  Korean Circ J       Date:  2013-03-31       Impact factor: 3.243

Review 7.  Antiepileptic drug-induced pharmacodynamic aggravation of seizures: does valproate have a lower potential?

Authors:  Edouard Hirsch; Pierre Genton
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 8.  Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review.

Authors:  M F B Silva; C C P Aires; P B M Luis; J P N Ruiter; L IJlst; M Duran; R J A Wanders; I Tavares de Almeida
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.982

Review 9.  Genetic stroke syndromes.

Authors:  Kevin M Barrett; James F Meschia
Journal:  Continuum (Minneap Minn)       Date:  2014-04

10.  Treatment of mitochondrial disorders.

Authors:  Sreenivas Avula; Sumit Parikh; Scott Demarest; Jonathan Kurz; Andrea Gropman
Journal:  Curr Treat Options Neurol       Date:  2014-06       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.